Cue Biopharma saw the highest growth of 5.99% in patent filings and 3.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.19% and grants by 0.32%. GlobalData’s DataBook provides a comprehensive analysis of Cue Biopharma’s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Cue Biopharma has been focused on protecting inventions in United States(US) with 13 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 69% filings and 57% grants. The United States(US), European Patent Office(EPO), Australia(AU), and Israel(IL) patent Office are among the top ten patent offices where Cue Biopharma is filings its patents. Among the top granted patent authorities, Cue Biopharma has 57% of its grants in United States(US), 29% in Israel(IL) and 14% in Slovenia(SI).
Regeneron Pharmaceuticals and Immatics could be the strongest competitors for Cue Biopharma
Cue Biopharma stands in second position with respect to its patent publications among its competitors.
Patents related to rare diseases and cell & gene therapy lead Cue Biopharma's portfolio
Cue Biopharma has the highest number of patents in rare diseases followed by, cell & gene therapy. For rare diseases, nearly 80% of patents were filed and no patents were granted in Q2 2024.
Cervical cancer related patents lead Cue Biopharma portfolio followed by head and neck cancer, and human papillomavirus infections
Cue Biopharma has highest number of patents in cervical cancer followed by head and neck cancer, human papillomavirus infections, addison's disease (primary or chronic adrenal insufficiency), and melanoma. For cervical cancer, nearly 4% of patents were filed and 27% of patents were granted in Q2 2024.
For comprehensive analysis of Cue Biopharma's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
